These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 7710444)

  • 1. Single dose pharmacokinetics and tolerance of pancopride in healthy volunteers.
    Dewland P; Pérez Campos A; Martinez-Tobed A
    Arzneimittelforschung; 1995 Feb; 45(2):177-83. PubMed ID: 7710444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated dose pharmacokinetics of pancopride in human volunteers.
    Salva P; Costa J; Pérez-Campos A; Martínez-Tobed A
    Biopharm Drug Dispos; 1994 Nov; 15(8):643-51. PubMed ID: 7888596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical development of an antiemetic in oncology. A meta-analysis].
    Pérez Campos A
    Med Clin (Barc); 1994 Sep; 103(8):281-6. PubMed ID: 7967877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of a 5-HT3 antagonist, pancopride, on lower oesophageal sphincter pressure in volunteers.
    Grande L; Lacima G; Pérez A; Zayas JM
    Br J Clin Pharmacol; 1995 Oct; 40(4):401-3. PubMed ID: 8554943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis.
    Fernández AG; Puig J; Beleta J; Doménech T; Bou J; Berga P; Gristwood RW; Roberts DJ
    Eur J Pharmacol; 1992 Nov; 222(2-3):257-64. PubMed ID: 1451737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of deramciclane during multiple oral dosing.
    Kanerva H; Kilkku O; Helminen A; Rouru J; Scheinin M; Huupponen R; Klebovich I; Drabant S; Urtti A
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):589-97. PubMed ID: 10599951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and pharmacokinetics of Ro 42-1611 (arteflene) in man.
    Weidekamm E; Dumont E; Jaquet C
    Trop Med Parasitol; 1994 Sep; 45(3):278-83. PubMed ID: 7899804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emesis and defecations induced by the 5-hydroxytryptamine (5-HT3) receptor antagonist zacopride in the ferret.
    King GL
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1034-41. PubMed ID: 2162943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.
    Farré M; Roset PN; Llorente M; Márquez M; Albet C; Pérez JA; Herrero E; Ortíz JA
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):343-50. PubMed ID: 9379783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remoxipride--a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers.
    Grind M; Nilsson MI; Nilsson L; Oxenstierna G; Sedvall G; Wahlén A
    Psychopharmacology (Berl); 1989; 98(3):304-9. PubMed ID: 2568653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. General pharmacology of a new potent 5-hydroxytryptamine antagonist.
    Williams PD; Calligaro DO; Colbert WE; Helton DR; Shetler T; Turk JA; Jordan WH
    Arzneimittelforschung; 1991 Mar; 41(3):189-95. PubMed ID: 1867653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.
    Weber C; Schmitt R; Birnboeck H; Hopfgartner G; van Marle SP; Peeters PA; Jonkman JH; Jones CR
    Clin Pharmacol Ther; 1996 Aug; 60(2):124-37. PubMed ID: 8823230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-ranging trial of zacopride: the emetic antiemetic?
    Pisters KM; Kris MG; Tyson LB; Clark RA; Gralla RJ
    J Natl Cancer Inst; 1992 May; 84(9):717-8. PubMed ID: 1569606
    [No Abstract]   [Full Text] [Related]  

  • 15. LAS 30451: a novel 5-HT3 antagonist.
    Martin M; Rosell R; Guillem V; Díaz-Rubio E; Moreno I; Soriano V; Fernández A; Pérez A
    Eur J Cancer; 1993; 29A Suppl 1():S33-4. PubMed ID: 8427723
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers.
    Clark AM; Kriel RL; Leppik IE; Marino SE; Mishra U; Brundage RC; Cloyd JC
    Epilepsia; 2013 Jun; 54(6):1099-105. PubMed ID: 23506041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic study of bisaramil in man.
    Gémesi L; Kapás M; Matos L
    Acta Pharm Hung; 1993 Nov; 63(6):327-33. PubMed ID: 8116453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on general behaviour and neurotransmitter functions of a new 5-hydroxytryptamine3 receptor antagonist with potential therapeutic relevance in central nervous system disturbances.
    Rizzi CA; Prudentino A; Giraldo E
    Arzneimittelforschung; 1993 Oct; 43(10):1033-41. PubMed ID: 7903536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
    Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
    Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J; Kubitza D; Becka M; Mueck W
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.